BNT411 + atezolizumab + carboplatin + etoposide

This is a combination regimen consisting of **BNT411** (a TLR7 agonist immunomodulator), **atezolizumab** (a monoclonal antibody targeting PD-L1 and immune checkpoint inhibitor), **carboplatin** (a platinum-based chemotherapy agent), and **etoposide** (a topoisomerase II inhibitor chemotherapeutic). BNT411 is developed to activate the innate immune response through TLR7 to enhance anti-tumor immunity. Atezolizumab blocks the PD-L1 checkpoint, thereby promoting the adaptive immune system's ability to attack tumor cells. Carboplatin and etoposide are cytotoxic chemotherapies that induce DNA damage and cell death, especially effective in rapidly dividing cells. The combination is being investigated primarily in extensive-stage small cell lung cancer (ES-SCLC) and solid tumors to determine enhanced efficacy by synergizing immune activation and cytotoxic therapy[1][3][5][7].

Other names

atezolizumabcarboplatinetoposide